Kidney Transplantation in Patients With Active SARS-CoV-2 Replication: An Initial Case Series.
作者信息
Halfon Matthieu, Stavart Louis, Venetz Jean-Pierre, Manuel Oriol, Golshayan Dela
机构信息
Transplantation Center, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
出版信息
Transpl Int. 2022 Aug 25;35:10716. doi: 10.3389/ti.2022.10716. eCollection 2022.
Abstract
摘要
相似文献
1
Kidney Transplantation in Patients With Active SARS-CoV-2 Replication: An Initial Case Series.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）活跃复制患者的肾移植：首例病例系列报道
Transpl Int. 2022 Aug 25;35:10716. doi: 10.3389/ti.2022.10716. eCollection 2022.
2
Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.血清学反应和抗 SARS-CoV-2 疫苗接种的临床保护作用，以及免疫抑制药物在一组肾移植患者中的作用。
Viruses. 2022 Sep 2;14(9):1951. doi: 10.3390/v14091951.
3
Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients.雷帕霉素和菊粉增强疫苗反应刺激（RIVASTIM）-雷帕霉素：一项随机对照试验的研究方案，旨在用雷帕霉素调节免疫抑制，改善肾移植受者对 SARS-CoV-2 疫苗的反应。
Trials. 2022 Sep 15;23(1):780. doi: 10.1186/s13063-022-06634-w.
4
Kidney transplantation from a SARS-CoV-2-positive donor for the recipients with immunity after COVID-19.COVID-19 后免疫的受者接受 SARS-CoV-2 阳性供者的肾移植。
Transpl Infect Dis. 2021 Aug;23(4):e13666. doi: 10.1111/tid.13666. Epub 2021 Jun 22.
5
Humoral Response in SARS-CoV-2 Convalescent Compared to Vaccinated Kidney Transplant Patients.与接种疫苗的肾移植患者相比，新冠康复者的体液免疫反应
Transpl Int. 2022 Jan 18;35:10060. doi: 10.3389/ti.2021.10060. eCollection 2021.
6
Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients.抗SARS-CoV-2单克隆抗体预防和疫苗接种对肾移植受者中新冠病毒奥密克戎变异株的疗效
Kidney Int. 2022 Aug;102(2):440-442. doi: 10.1016/j.kint.2022.05.007. Epub 2022 May 23.
7
A case of severe COVID-19 despite full vaccination with mRNA-1273 SARS-CoV-2 vaccine (Moderna) in a kidney transplant recipient.一名肾移植受者尽管已全程接种mRNA-1273新冠病毒疫苗（Moderna），仍感染了重症新冠病毒。
Transpl Infect Dis. 2021 Oct;23(5):e13710. doi: 10.1111/tid.13710. Epub 2021 Aug 16.
8
Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine.移植前接种疫苗的肾移植受者对 SARS-CoV-2 疫苗保持优越的体液反应。
Clin Transplant. 2021 Dec;35(12):e14478. doi: 10.1111/ctr.14478. Epub 2021 Sep 29.
9
Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.肾移植患者接种 SARS-CoV-2 疫苗后的免疫反应。
Medicina (Kaunas). 2021 Dec 3;57(12):1327. doi: 10.3390/medicina57121327.
10
Observations on improving COVID-19 vaccination responses in kidney transplant recipients: heterologous vaccination and immunosuppression modulation.关于改善肾移植受者新冠病毒疫苗接种反应的观察：异源疫苗接种和免疫抑制调节
Kidney Int. 2022 Mar;101(3):642-645. doi: 10.1016/j.kint.2021.11.024. Epub 2021 Dec 8.
本文引用的文献
1
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.丹麦的一项观察性队列研究：感染 SARS-CoV-2 奥密克戎变异株与德尔塔变异株导致住院的风险比较。
Lancet Infect Dis. 2022 Jul;22(7):967-976. doi: 10.1016/S1473-3099(22)00154-2. Epub 2022 Apr 22.
2
Safety of Antithymocyte Globulin Use in Kidney Graft Recipients During the COVID-19 Pandemic.COVID-19 大流行期间肾移植受者使用抗胸腺细胞球蛋白的安全性。
Ann Transplant. 2021 Oct 26;26:e933001. doi: 10.12659/AOT.933001.
3
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant.RECOVAC IR研究：mRNA-1273新冠疫苗在慢性肾病患者、接受透析患者或肾移植受者中的免疫反应及安全性
Nephrol Dial Transplant. 2021 Aug 27;36(9):1761-1764. doi: 10.1093/ndt/gfab186.
4
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.血液透析患者和肾移植受者队列中 SARS-CoV-2 mRNA 疫苗接种后的体液反应。
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158. doi: 10.1681/ASN.2021040490. Epub 2021 Jun 16.
5
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.接受利妥昔单抗治疗的炎症性风湿和肌肉骨骼疾病患者的COVID-19结局：一项队列研究。
Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25.
6
COVID-19 in Immunocompromised Hosts: What We Know So Far.免疫功能低下宿主中的 COVID-19：目前我们已知的情况。
Clin Infect Dis. 2021 Jan 27;72(2):340-350. doi: 10.1093/cid/ciaa863.
7
T-cell responses and therapies against SARS-CoV-2 infection.T 细胞应答与针对 SARS-CoV-2 感染的治疗方法。
Immunology. 2021 Jan;162(1):30-43. doi: 10.1111/imm.13262. Epub 2020 Oct 27.
Zotero 插件